Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy

BACKGROUND: The immune checkpoint blockade (ICB) targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) has been proved beneficial for numerous types of cancers, including non-small-cell lung cancer (NSCLC). However, a significant number of patients with NSCLC still fail to respond to ICB d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chia-Sing, Lin, Ching-Wen, Chang, Ya-Hsuan, Chen, Hsuan-Yu, Chung, Wei-Chia, Lai, Wei-Yun, Ho, Chao-Chi, Wang, Tong-Hong, Chen, Chi-Yuan, Yeh, Chen-Lin, Wu, Sean, Wang, Shu-Ping, Yang, Pan-Chyr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692992/
https://www.ncbi.nlm.nih.gov/pubmed/33243934
http://dx.doi.org/10.1136/jitc-2020-001392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692992/
https://www.ncbi.nlm.nih.gov/pubmed/33243934
http://dx.doi.org/10.1136/jitc-2020-001392

Ejemplares similares